Little S, Eberts M, Breitschwerdt EB, Beall MJ, Chandrashekar R, 2014. Performance of a commercially available in-clinic ELISA for detection of antibodies against *Anaplasma phagocytophilum*, *Anaplasma platys*, *Borrelia burgdorferi*, *Ehrlichia canis*, and *Ehrlichia ewingii* and *Dirofilaria immitis* antigen in dogs. J Am Vet Med Assoc 245:80-6.

Stone EG, Lacombe EH, Rand PW, 2005. Antibody testing and Lyme disease risk. Emerg Infect Dis 11:722-4.

Ting Liang F, Jacobson RH, Straubinger RK, Grooters A, Philipp MT, 2000. Characterization of a *Borrelia burgdorferi* VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay. J Clin Microbiol 38:4160-6.

Tseng Y-J, Cami A, Goldmann DA, DeMaria Jr A, Mandl KD, 2015. Using nation-wide health insurance claims data to augment Lyme disease surveillance. Vector Borne Zoonotic Dis 15:591-6.

Tuite AR, Greer AL, Fisman DN, 2013. Effect of latitude on the rate of change in incidence of Lyme disease in the United States. CMAJ Open 1:E43-7.

Wagner B, Freer H, Rollins A, Garcia-Tapia D, Erb HN, Earnhart C, Marconi R, Meeus P, 2012. Antibodies to *Borrelia burgdorferi* OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs. Clin Vaccine Immunol 19:527-35.

Walter KS, Pepin KM, Webb CT, Gaff HD, Krause PJ, Pitzer VE, Diuk-Wasser MA, 2016. Invasion of two tick-borne diseases across New England: harnessing human surveillance data to capture underlying ecological invasion processes. Proc Biol Sci 283.

Watson SC, Liu Y, Lund RB, Gettings JR, Nordone SK, McMahan CS, Yabsley MJ, 2017. A Bayesian spatio-temporal model for forecasting the prevalence of antibodies to *Borrelia burgdorferi*, causative agent of Lyme disease, in domestic dogs within the contiguous United States. PLoS One 5:e0174428.

White J, Noonan-Toly C, Lukacik G, Thomas N, Hinckley A, Hook S, Backenson P, 2016. Lyme disease surveillance in New York state: An assessment of case underreporting. Zoonoses Public Health 65:238-46.

Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJ, Dumler JS, 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75:9-15.